0000899243-22-031603.txt : 20220920
0000899243-22-031603.hdr.sgml : 20220920
20220920180028
ACCESSION NUMBER: 0000899243-22-031603
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220916
FILED AS OF DATE: 20220920
DATE AS OF CHANGE: 20220920
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Ahrens Brenton Karl
CENTRAL INDEX KEY: 0001322927
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38503
FILM NUMBER: 221254657
MAIL ADDRESS:
STREET 1: 2765 SAND HILL ROAD
CITY: MENLO PARK
STATE: CA
ZIP: 94025
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Iterum Therapeutics plc
CENTRAL INDEX KEY: 0001659323
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: L2
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: FITZWILLIAM COURT, 1ST FLOOR
STREET 2: LEESON CLOSE
CITY: DUBLIN 2
STATE: L2
ZIP: D02 YW24
BUSINESS PHONE: (872) 225-6077
MAIL ADDRESS:
STREET 1: FITZWILLIAM COURT, 1ST FLOOR
STREET 2: LEESON CLOSE
CITY: DUBLIN 2
STATE: L2
ZIP: D02 YW24
FORMER COMPANY:
FORMER CONFORMED NAME: Iterum Therapeutics Ltd
DATE OF NAME CHANGE: 20151124
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-09-16
0
0001659323
Iterum Therapeutics plc
ITRM
0001322927
Ahrens Brenton Karl
C/O CANAAN PARTNERS
285 RIVERSIDE AVE., SUITE 250
WESTPORT
CT
06880
1
0
0
0
Ordinary Shares
2022-09-16
4
S
0
15000
1.9028
D
22246
I
See Footnote
Ordinary Shares
2022-09-19
4
S
0
15000
1.7652
D
7246
I
See Footnote
Ordinary Shares
2022-09-20
4
S
0
7246
1.7817
D
0
I
See Footnote
Ordinary Shares
410
D
The number of Ordinary Shares described herein reflect a 15:1 reverse stock split by the Issuer which became effective August 17, 2022.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.85 - $2.00, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
These shares are held directly by Canaan X L.P. (the "Canaan Fund"). The sole general partner of the Canaan Fund is Canaan Partners X LLC ("Canaan X", and together with the Canaan Fund, the "Canaan Entities"). Investment and voting decisions with respect to the securities held by the Canaan Fund are made by the managers of Canaan X, collectively. The Reporting Person, a manager and member of Canaan X, serves as the representative of the Canaan Entities on the Issuer's board of directors. The Reporting Person disclaims Section 16 beneficial ownership in the securities held by the Canaan Entities, except to the extent of his pecuniary interest therein, if any, in such securities by virtue of the limited liability company interests he owns in Canaan X.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.70 - $1.87, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.77 - $1.81, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
By: /s/ Nancy Levenson, as Attorney-in-Fact for Brenton Karl Ahrens
2022-09-20